SCHEMBL555278

SCHEMBL555278

CC(=O)N[C@@H](C=O)[C@@H](OP(=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@H](O)[C@@H]1O)OP(=O)(O)O)[C@H](O)[C@H](O)CO

nearest known ligand 0.52

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
P2RY2 P41231 11/20 0.52
P2RY6 Q15077 8/20 0.52
P2RY4 P51582 7/20 0.52
P2RY14 Q15391 6/20 0.52
OGT O15294 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1519760 1.00 P2RY2 (0.52) P2RY2P2RY6P2RY4P2RY14OGT
Pyruvate SCHEMBL11424485 0.97 P2RY2 (0.50) P2RY2P2RY6P2RY4P2RY14OGT
SCHEMBL875379 0.94 P2RY2 (0.53) P2RY2P2RY6P2RY4P2RY14OGT
SCHEMBL6421384 0.94 P2RY2 (0.52) P2RY2P2RY6P2RY4P2RY14OGT
SCHEMBL15333769 0.94 P2RY2 (0.53) P2RY2P2RY6P2RY4P2RY14OGT
SCHEMBL8373272 0.90 P2RY2 (0.54) P2RY2P2RY6P2RY4P2RY14OGT
SCHEMBL2491234 0.90 P2RY2 (0.54) P2RY2P2RY6P2RY4P2RY14OGT
Uridine_Diphosphate SCHEMBL404650 0.89 P2RY6 (0.61) P2RY2P2RY6P2RY4P2RY14OGT
Uridine_Diphosphate SCHEMBL3508085 0.89 P2RY6 (0.61) P2RY2P2RY6P2RY4P2RY14OGT
Uridine_Diphosphate SCHEMBL28093501 0.89 P2RY6 (0.61) P2RY2P2RY6P2RY4P2RY14OGT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 265 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11767546-B2 Enzymatic method for preparation of UDP-GlcNAc MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2023-09-26 US claimed
US-11739358-B2 Enzymatic method for preparation of UDP-galactose MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2023-08-29 US claimed
EP-3874056-B1 ENZYMATIC METHOD FOR PREPARATION OF UDP-GLCNAC MAX PLANCK GESELLSCHAFT (DE) 2023-06-14 EP claimed
US-20230060588-A1 METHODS OF AMELIORATING AND/OR PREVENTING CORONAVIRUS-RELATED INFECTIONS Glycure LLC (US) 2023-03-02 US claimed
US-20220380820-A1 ENZYMATIC METHOD FOR PREPARATION OF UDP-GLCNAC MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2022-12-01 US claimed
EP-3874056-A1 ENZYMATIC METHOD FOR PREPARATION OF UDP-GLCNAC Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2021-09-08 EP claimed
US-11060074-B2 Self-regenerating hyaluronan polymer brushes GEORGIA TECH RESEARCH CORPORATION (US) 2021-07-13 US claimed
EP-3819382-A1 ENZYMATIC METHOD FOR PREPARATION OF UDP-GLCNAC Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2021-05-12 EP claimed
US-20190276807-A1 Self-Regenerating Hyaluronan Polymer Brushes GEORGIA TECH RESEARCH CORPORATION 2019-09-12 US claimed
US-20180194794-A1 Activated N-Acetylated Sugars and Oligosaccharides ZUCHEM INC (US) 2018-07-12 US claimed
US-7005279-B1 Process for producing carbohydrates using β 1,3-N-acetyl-glucosaminyltransferase KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-02-28 US claimed
WO-2005025556-A2 ANTIBIOTIC CYCLOALKYLTETRAHYDROQUINOLINE DERIVATIVES OSCIENT PHARMACEUTICALS (US) 2005-03-24 WO claimed
US-20050019874-A1 Processes for producing sugar nucleotides and complex carbohydrates KYOWA HAKKO KOGYO CO., LTD. (JP) 2005-01-27 US claimed
US-6589762-B1 Incubating test sample in culture of fungus containing the fluorochrome and observing cell growth; use in identification of potential fungicides and insecticides BASF AKTIENGESELLSCHAFT (DE) 2003-07-08 US claimed
US-20020064836-A1 PROCESSES FOR PRODUCING SUGAR NUCLEOTIDES AND COMPLEX CARBOHYDRATES KYOWA HAKKO BIO CO., LTD. (JP) 2002-05-30 US claimed
EP-1197556-A1 USEFUL POLYPEPTIDE KYOWA HAKKO KOGYO CO., LTD. (JP) 2002-04-17 EP claimed
US-20020025560-A1 Processes for producing sugar nucleotides and complex carbohydrates KYOWA HAKKO BIO CO., LTD. (JP) 2002-02-28 US claimed
EP-0870841-A1 PROCESSES FOR PRODUCING SUGAR NUCLEOTIDES AND COMPLEX CARBOHYDRATES KYOWA HAKKO KOGYO CO., LTD. (JP) 1998-10-14 EP claimed
US-5707846-A DERIVED FROM HUMAN LUNG CANCER CELLS SUNTORY LIMITED (JP) 1998-01-13 US claimed
EP-0334962-A1 METHOD FOR DIAGNOSIS OF HEPATIC CANCER OR HEPATOCIRRHOSIS ORIENTAL YEAST CO., LTD. (JP) 1989-10-04 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230060588-A1 METHODS OF AMELIORATING AND/OR PREVENTING CORONAVIRUS-RELATED INFECTIONS FUT5, FUT6, SIGLEC7 P2RY2 4000/4885P2RY6 3215/4885P2RY4 3553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.